Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

To characterize the clinical course and outcomes of children 12-18 years of age who developed probable myopericarditis after vaccination with the Pfizer-BioNTech (BNT162b2) coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine. A cross-sectional study of 25 children, aged 12-18 years, dia...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pediatrics 2021-11, Vol.238, p.26-32.e1
Main Authors: Das, Bibhuti B., Kohli, Utkarsh, Ramachandran, Preeti, Nguyen, Hoang H., Greil, Gerald, Hussain, Tarique, Tandon, Animesh, Kane, Colin, Avula, Sravani, Duru, Chioma, Hede, Sannya, Sharma, Kavita, Chowdhury, Devyani, Patel, Sunil, Mercer, Christopher, Chaudhuri, Nita Ray, Patel, Bhavi, Ang, Jocelyn Y., Asmar, Basim, Sanchez, Joselito, Khan, Danyal
Format: Article
Language:English
Subjects:
Adolescent
Child
COVID-19 - epidemiology
COVID-19 - genetics
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - genetics
Cross-Sectional Studies
Female
Humans
Incidence
Magnetic Resonance Imaging, Cine - methods
Male
mRNA COVID-19 vaccine
mRNA Vaccines
myocarditis
Myocarditis - diagnosis
Myocarditis - epidemiology
Myocarditis - etiology
Original
Pandemics
pericarditis
Retrospective Studies
SARS-CoV-2 - immunology
United States - epidemiology
Vaccination - adverse effects
Vaccines, Synthetic - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To characterize the clinical course and outcomes of children 12-18 years of age who developed probable myopericarditis after vaccination with the Pfizer-BioNTech (BNT162b2) coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine. A cross-sectional study of 25 children, aged 12-18 years, diagnosed with probable myopericarditis after COVID-19 mRNA vaccination as per the Centers for Disease Control and Prevention criteria for myopericarditis at 8 US centers between May 10, 2021, and June 20, 2021. We retrospectively collected the following data: demographics, severe acute respiratory syndrome coronavirus 2 virus detection or serologic testing, clinical manifestations, laboratory test results, imaging study results, treatment, and time to resolutions of symptoms. Most (88%) cases followed the second dose of vaccine, and chest pain (100%) was the most common presenting symptom. Patients came to medical attention a median of 2 days (range,
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2021.07.044